Jefferies Group LLC restated their buy rating on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research report released on Thursday. Jefferies Group LLC currently has a $19.00 price target on the stock, up from their prior price target of $16.00. Jefferies Group also issued estimates for Karyopharm Therapeutics’ Q3 2017 earnings at ($0.63) EPS, Q4 2017 earnings at ($0.65) EPS, FY2017 earnings at ($2.63) EPS, FY2018 earnings at $0.07 EPS, FY2019 earnings at ($1.71) EPS, FY2020 earnings at ($0.28) EPS and FY2021 earnings at ($0.24) EPS.

A number of other analysts have also weighed in on KPTI. Cantor Fitzgerald reaffirmed an overweight rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday, May 15th. ValuEngine lowered Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, May 25th. Robert W. Baird reaffirmed an outperform rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Zacks Investment Research raised Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 price objective on the stock in a research report on Thursday, July 6th. Finally, BidaskClub lowered Karyopharm Therapeutics from a sell rating to a strong sell rating in a research report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $14.56.

Karyopharm Therapeutics (KPTI) traded up 3.04% on Thursday, reaching $8.81. The company’s stock had a trading volume of 50,456 shares. The firm’s market capitalization is $415.29 million. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The company has a 50 day moving average of $9.11 and a 200 day moving average of $10.01.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same quarter last year, the company earned ($0.84) EPS. The firm’s quarterly revenue was down 95.0% compared to the same quarter last year. On average, analysts forecast that Karyopharm Therapeutics will post ($2.69) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/14/karyopharm-therapeutics-kpti-buy-rating-reiterated-at-jefferies-group-llc.html.

Institutional investors have recently bought and sold shares of the stock. Voya Investment Management LLC raised its position in Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after buying an additional 4,444 shares during the period. Teza Capital Management LLC acquired a new position in Karyopharm Therapeutics during the first quarter valued at approximately $169,000. Trexquant Investment LP acquired a new position in Karyopharm Therapeutics during the second quarter valued at approximately $202,000. Metropolitan Life Insurance Co. NY raised its position in Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares during the period. Finally, American International Group Inc. raised its position in Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares during the period. 57.58% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.